Genmab A/S
GMAB
NASDAQ·Healthcare·Biotechnology·Mkt cap $20.6B
$33.60
▼ -2.35%
P/E
54.89
Mkt Cap
$20.6B
52-Wk Range
$23.62–$35.43
52-Week Range
$23.62 - $35.43
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 22.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary antibody technology platform and manufacturing expertise
- Diversified portfolio with marketed blockbuster products and deep pipeline
- Strategic partnerships with major pharmaceutical companies (Janssen, AbbVie, Seagen)
- Strong intellectual property position and patent protection
Bear Case
2 risks
- Low volatility (beta 0.7).
- Premium valuation to Biotech & Therapeutics peers
Growth
Stable outlook
Expanding DARZALEX and daratumumab market penetration in multiple indications
Value
Premium valuation to Biotech & Therapeutics peers
Momentum
Hot
+33.6% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GMAB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $0.54 vs $0.37 consensus (+46.0% surprise). Revenue of $1.2B vs $1.1B expected (+3.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+46.0%
Revenue trend · last 8Q
—
—
+19%
+652%
-82%
-84%
+26%
+25%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$859.9M
$999.7M
$111.0M
$909.8M
$158.6M
$163.7M
$139.6M
$1.2B
Margins · last 8Q
Gross
92.7%
Operating
35.2%
Profit
26.2%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Deutsche Bank · Sep 1, 2026
vs Industry
How GMAB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related